Chongqing Lummy Pharmaceutical Co.Ltd(300006) : financial statement report of 2021

Chongqing Lummy Pharmaceutical Co.Ltd(300006)

Financial statement report of 2021

Chongqing Lummy Pharmaceutical Co.Ltd(300006) (hereinafter referred to as “the company”) the balance sheet of the parent company and the merger on December 31, 2021, the profit statement of the parent company and the merger in 2021, the cash flow statement of the parent company and the merger in 2021, the statement of changes in owner’s equity of the parent company and the merger in 2021 and the notes to relevant statements have been audited by Sichuan Huaxin (Group) Certified Public Accountants (special general partnership) and issued a standard unqualified audit report.

1、 Basic information

In 2021, the company realized a total operating income of 1225224200 yuan, a year-on-year decrease of 22.63%; do business

Profit -701417 million yuan, net profit -1059373 million yuan; The total assets are 29267739 million yuan, of which

Current assets are 1726995300 yuan and non current assets are 1199778700 yuan; The total liabilities are 7146472

10000 yuan; The owner’s equity is 2212126700 yuan, of which the owner’s equity attributable to the parent company is 2156345400 yuan.

2、 Consolidation scope during the reporting period

No. name of subsidiary company registered place business nature shareholding proportion acquisition method

Direct and indirect

Chongqing Laimei Pharmaceutical Co., Ltd. obtained 100.00% of the business merger under the same control of pharmaceutical circulation in Chongqing north new area

Hunan Kangyuan Pharmaceutical Co., Ltd. Hunan Liuyang Pharmaceutical Manufacturing Co., Ltd. is not under the same control, with a total of 2 100.00% and achieved

3. Chongqing Laimei medical device Co., Ltd. was established in Chongqing Nan’an District with 100% success

4 Hunan Kangyu Medical Instrument Co., Ltd. was established in Hunan Liuyang with 100% success

Chongqing Laimei Jude pharmaceutical chain Co., Ltd. has made achievements in the establishment of pharmaceutical circulation in Chongqing north new area

5. 100.00%

6. 75.00% of Chengdu Health Consulting Co., Ltd. of Aijia special line Health Management Co., Ltd. was established

Butterfly housekeeper (Chengdu) Health Management Co., Ltd. was established in Chengdu, Sichuan Province

7. 75.00%

8. Chengdu Wuhou jiaruai clinic Co., Ltd. was established in 75.00% of medical consultation in Chengdu, Sichuan

9 Chongqing Laimei Longyu Pharmaceutical Co., Ltd. was established in Chongqing Changshou Pharmaceutical Manufacturing Co., Ltd. at 100.00%

10. Laimei (Hong Kong) Co., Ltd. has obtained 100.00% of the establishment of Hong Kong Chaiwan investment business

Chengdu Jinxing Health Pharmaceutical Co., Ltd. Chengdu Jinniu District immune preparation enterprises not under the same control accounted for 11 90.00% and achieved

Sichuan kantsai Medical Technology Co., Ltd. has made achievements in the establishment of medical technology development in Chengdu high tech Zone

12 rounds 37.17%

13. Sichuan Yingrui Pharmaceutical Technology Co., Ltd. was established in 61.00% of the pharmaceutical research of Chengdu high tech Zone

14 Tibet Laimei Deji Pharmaceutical Co., Ltd. Lhasa pharmaceutical circulation 51.00% of enterprises not under the same control

And obtain

Changzhou Laimei Qingfeng pharmaceutical industry investment center Changzhou investment business other 15 (limited partnership) 29.90%

Beijing Lantian shared health management Co., Ltd. Beijing pharmaceutical promotion Co., Ltd. 80.00%

17. Beijing Yaohua fragrance Pharmaceutical Technology Co., Ltd. was established in 100.00% of Beijing pharmaceutical promotion

Guangzhou Saifu health industry investment partnership Guangzhou investment business other 18 (limited partnership) 47.96%

19. Xianzan medical devices (Hainan) Co., Ltd. has achieved 43.90% of the establishment of medical devices in Hainan Province

Chongqing tungshi Zhiyuan biomedical intellectual property establishment of Chongqing north new area investment business achieved 68.85% of 20 investment partnerships (limited partnerships)

By the end of the reporting period, the company had 8 wholly-owned subsidiaries and 12 holding subsidiaries.

3、 Financial situation

1. Asset status

Unit: Yuan

Change rate of project amount from December 31, 2021 to December 31, 2020

Notes receivable 76874070197068081 -120194011 -60.99%

Receivables financing 22767507054669931262 -2393180557 -51.25%

Other receivables 539131092322867955409825233555134 87.98%

Inventory 1577745732829665488958 -13888031630 -46.82%

Other current assets 449850036740581102 – 290731066 – 39.26%

Long term equity investment 937246068324682020571 – 15309559888 – 62.03%

Investment real estate 183807536686541692 – 502734156 – 73.23%

Construction in progress 4094728841684241317 – 1274768433 – 75.69%

(1) The ending balance of notes receivable in the reporting period decreased by 1201900 yuan or 60.99% compared with that at the beginning of the reporting period, mainly due to the decrease of commercial acceptance bills received in the reporting period.

(2) The ending balance of receivables financing in the reporting period decreased by 239318 million yuan or 51.25% compared with the beginning of the period, mainly due to the decrease of bank acceptance bills received in the reporting period.

(3) The ending balance of other receivables in the reporting period increased by 252335600 yuan or 87.98% compared with the beginning of the reporting period, mainly due to the increase of equity transfer funds, contracted operation funds and other receivables formed by the agency business of lemmeric Deji.

(4) The ending balance of inventory in the reporting period decreased by 1388803 million yuan or 46.82% compared with that at the beginning of the reporting period, mainly due to the sharp decline in sales of some varieties affected by the centralized purchase policy in the reporting period and the corresponding decrease in inventory at the end of the year. (5) The ending balance of other current assets in the reporting period decreased by 2.9073 million yuan or 39.26% compared with that at the beginning of the reporting period, mainly due to the decrease of prepaid and deductible taxes in the reporting period.

(6) The ending balance of long-term equity investment in the reporting period decreased by 1530956 million yuan or 62.03% compared with that at the beginning of the reporting period, which is mainly due to the transfer of the equity of Chengdu Meikang Pharmaceutical Information System Co., Ltd. and Sichuan Meikang pharmaceutical software research and Development Co., Ltd., an associate accounted for by the equity method of long-term equity investment in the reporting period.

(7) The ending balance of investment real estate in the reporting period decreased by 5.0273 million yuan or 73.23% compared with the beginning of the reporting period, mainly due to the changes in the scope of consolidated statements in the reporting period.

(8) The ending balance of construction in progress in the reporting period decreased by RMB 127477 million or 75.69% compared with that at the beginning of the reporting period, which is mainly due to the solid transformation of phase II and phase I of the industrialization production base of anti infection and special medicine raw materials in the reporting period. 2. Liability status

Unit: Yuan

Change rate of project amount from December 31, 2021 to December 31, 2020

Short term loan 1300000 China High-Speed Railway Technology Co.Ltd(000008) 9448925950 – 76448925950 – 85.47%

Notes payable – 368008126 – 368008126 – 100%

Accounts payable 34260949076571360055 -3145265148 -47.86%

Contract liabilities 13066763712467871395 – 1161195024 – 47.05%

Non current assets due within one year

Current liabilities 554114586320396352461 -14855206598 -72.83%

Other current liabilities 169855918311890009 – 1420,